Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients with Molecularly Selected Cancers (ATTACC)
Contact:
NCT Number:
Protocol:
AAAT7370
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
The study is being done to learn how safe and effective the study drug, RP- 3500, is when given with either niraparib or olaparib to treat advanced cancer. Niraparib and olaparib belong to a group of drugs called PARP inhibitors. These drugs are designed to block an enzyme called PARP which may stop cancer cells from growing. RP 3500 belongs to a class of drugs called ATR inhibitors that are design to stop cancer cells from growing.
Are you Eligible? (Inclusion Criteria)
- Aged 18 years or older.
- Diagnosed with locally advanced or metastatic cancer.
- Have not received prior therapy with another ATRi or DNA-PK inhibitor
Specialty Area(s)
Bladder Cancer , Brain and Spinal Tumors, Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Head and Neck/Oral Cancers, Liver Cancer, Lung cancer, Skin cancers, Melanoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
